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Introduction
“Drugs don’t work in patients who don’t take them.” 
Former US Surgeon General, C Everett Koop
Lipid-lowering medication, in conjunction with a healthy 
lifestyle, can significantly reduce the risk of cardiovascular 
disease. However, poor adherence (adherence is defined 
as taking the medication correctly and regularly, according 
to the instructions provided) and low rates of persistence 
(persistence with lipid-lowering medications is defined as 
continuing indefinitely) result in many patients not benefiting 
optimally. Failure to take lipid-lowering medication may 
result in the occurrence of preventable cardiovascular 
events in those for whom the primary goal of therapy is 
cardiovascular risk reduction. Patients who are being treated 
primarily for the control of severe hypertriglyceridaemia may 
experience potentially fatal acute pancreatitis. Improving 
adherence and persistence with medical therapy has the 
potential for great benefit, but is often difficult to achieve.1 
According to a recently published mathematical model of 
statin use in a population,2 specifically increasing statin 
persistence from 50-75% at five years, would prevent more 
cardiovascular events than lowering the risk threshold for 
prescribing statins. Spending more on lipid-lowering drugs 
does not prevent more events if patients do not actually 
take the drugs, or only take them for a few months. 
In everyday clinical practice, persistence rates with lipid-
lowering medication and other chronic medications are 
low.3,4 In a study of patients over the age of 65 years, only 
25% of patients continued to collect more than 80% of 
their medication supplies five years after statin therapy was 
initiated. Most patients discontinued treatment early, as 
evidenced by a six-month persistence rate of only 56%.3 
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Abstract
Many patients either do not adhere to, or fail to persist with, long-term lipid-lowering therapy. This unfavourable medication 
utilisation behaviour compromises potential treatment benefit. In retrospective studies, patients aged 50-65 had the highest 
adherence rates, while both younger and older patients had lower rates. Patients with pre-existing cardiovascular disease 
adhere better than those in primary prevention. Financial barriers may impair adherence. At the individual patient level, health 
beliefs, perceptions of own cardiovascular risk and need for medication, concerns about side-effects and inconvenience of 
treatment may influence adherence. In clinical trials, regular reminders to patients have been shown to improve adherence, 
but each patient will require an individually tailored treatment strategy. 
Myopathy is the most common clinically relevant adverse effect of statins. The clinical severity of statin myopathy is highly 
variable, ranging from mild muscle ache to rare instances of rhabdomyolysis. Risk factors for statin myopathy include age, 
statin dose, hypothyroidism, medications that inhibit statin metabolism, combined statin and fibrate therapy, and renal 
impairment. Alternative causes of myopathy should be excluded before muscular symptoms are ascribed to statins. The 
management of statin myopathy is guided by the severity of symptoms and the creatine kinase level. Potential management 
strategies include statin dechallenge and rechallenge, statin dose reduction, statin switching, non-daily dosing and use of 
alternative lipid-lowering agents, such as ezetimibe. 
Statins rarely cause severe liver disease. Mild liver enzyme elevations are seen relatively frequently in patients starting 
statins, but are usually not clinically important. Patients with persistently elevated liver enzymes should be investigated 
to determine the cause of liver disease. Patients with stable, well-compensated liver disease can be prescribed statins, 
provided they are closely monitored. 
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The reasons for nonadherence and nonpersistence are 
complex, and differ in each patient. This article will briefly 
review information on statin adherence and persistence, 
and then discuss some of the more common adverse 
effects of statins. 
Adherence and persistence
It is perhaps not surprising that long-term persistence 
with lipid-lowering medication is so low. Dyslipidaemia is 
usually asymptomatic until complications set in. Lipid-
lowering medications do not improve well-being, and at 
best, treated patients will feel no different. Some may 
even experience significant side-effects. Therefore, 
treatment of hyperlipidaemia usually involves asking 
patients to take long-term medication for a symptomless 
condition. Those who do not take their medication suffer 
no immediate consequences, except where there is severe 
hypertriglyceridaemia. Patients who fail to take their 
treatment for asthma, arthritis or reflux, to name only a 
few examples, do not feel well after a short period of non-
adherence, and usually resume treatment. 
In observational studies, statin adherence is associated 
with markedly reduced rates of cardiovascular disease, with 
the achieved event reduction often exceeding that seen in 
randomised clinical trials.5-8 However, this marked benefit 
is not entirely ascribable to lipid-lowering medication, as 
patients who adhere better are more likely to engage in other 
healthy behaviour. They are the so-called “healthy users”.9 
This is well exemplified in a recent study that showed that 
statin-adherent patients were less likely to be involved in 
traffic or workplace accidents, used screening services 
more frequently, and had a lower likelihood of developing 
diseases with no biological link to statin adherence.10 
Nonadherers do not only forego protection from statins, but 
also have riskier lifestyles.
Predictors of statin nonadherence
All studies on adherence are bedevilled by the methodological 
problem of measuring adherence accurately. Most rely on 
large medical funder databases, and quantify adherence by 
the number of prescriptions filled in a given time period. Of 
course, the fact that the patient collected the medication 
does not prove that it was taken, and patients who did 
not claim from their medical funders may have bought 
medicines privately. Nevertheless, pharmacy records are a 
reasonable proxy for adherence, as it is impossible and very 
intrusive to directly document adherence in large groups 
of patients. A recent meta-analysis of such record-based 
studies on statin adherence identified several predictors of 
poor adherence.11
The relationship between age and statin nonadherence is 
U-shaped. The nonadherence rates in patients younger than 
50 years are higher than those in patients aged 50-65 years. 
Adherence is best in this middle-aged group, and then 
decreases again with increasing age.11 Patient perception 
of cardiovascular risk may well influence adherence, with 
younger patients often perceiving themselves at lower risk, 
while heart disease is more of a reality for middle-aged 
adults. Low adherence rates in those over 70 years are 
probably multifactorial, with depression, polypharmacy, 
financial barriers and cognitive impairment all potentially 
contributing. 
Female gender predicts nonadherence (relative risk 1.07; 
95% confidence interval 1.04-1.11) in the majority of 
studies.11 Women access health care more frequently 
than men, and tend to pay more attention to their health.12 
Their lower reported adherence rate may reflect increased 
concern about side-effects, or a lesser perceived risk of 
heart disease, which is still often viewed as a predominantly 
male problem. 
Financial barriers are well known to influence adherence 
negatively. As out-of-pocket costs increase, adherence 
declines.13 Higher income is associated with lower rates of 
nonadherence in healthcare systems in which patients have 
to buy their own medication, or have to contribute to the 
cost.11 
Patients who have experienced a cardiovascular event are 
more likely to adhere to statins than those with additional 
risk factors, such as diabetes or hypertension. These 
patients correctly perceive themselves to be at increased 
risk, and are more likely to be motivated to continue taking 
statins.11
Patients taking other noncardiovascular medications are 
less likely to adhere to statins. This may be due to the 
increased complexity of their medication regimen and 
perceived lower benefit of statins when compared to 
medications directed at specific symptoms.11 Interestingly, 
a study that examined prescriptions in more detail, found 
that an increasing number of cardiovascular medications 
correlated with better adherence.14 Patients taking more 
cardiovascular medications are most likely to be sicker 
and at higher cardiovascular risk, and therefore perceive a 
greater benefit from taking satins. 
The demographic results from database-based studies 
can be used to identify patient populations that are at high 
risk of nonadherence, and who may benefit from additional 
counselling and monitoring. They do not solve the 
clinician’s dilemma of assessing the risk of and preventing 
nonadherence in the individual. Individual determinants of 
nonadherence are less well studied, but may include health 
beliefs, perceptions of the health system, self-efficacy, 
concerns about side-effects and depression.15 
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Members of a large American health maintenance 
organisation (Kaiser Permanente), that had a gap of at least 
one month in their statin supply, were invited to participate 
in focus groups to explore their reasons for nonadherence.16 
In this relatively small study of 18 patients, 15 different 
reasons for not taking statins were identified. 
The reasons can be grouped into four main categories:
•	 Concern	about,	or	experience	of,	adverse	effects: 
Very few patients suffered adverse effects, but concern 
was generated by reading package inserts, listening to 
friends and family, and searching the Internet.
•	 Uncertainty	about	the	benefit	of,	or	need	for,	
statins: Some patients stated that due to having high 
cholesterol, the lack of symptoms made them uncertain 
as to whether they actually needed treatment. 
•	 Lack	of	convenience: This accounted for a few 
discontinuations, with some patients stating that they 
did not like spending time collecting their medication 
and presenting for follow-up tests. 
•	 Other	reasons	were	varied: These included the desire 
to take a brand-name statin rather than a generic; 
being too ill to take the statin; and an unwillingness to 
stop drinking grapefruit juice. Taken in large quantities, 
grapefruit juice inhibits the metabolism of some statins. 
In this study, financial concerns were not prominent. All 
patients were insured and the required co-payment for 
statins was minimal. 
Patients were asked to identify factors that might help them 
improve their adherence. Many expressed a need to know 
more about statins, alternative therapies and statin side-
effects. Patients wanted longer consultations, more regular 
follow-ups, and regular reminders from their doctors. 
In another study of factors influencing statin adherence, 
313 Finnish patients with cardiovascular disease were 
presented with three different statements on statin therapy, 
and asked what their self-estimated adherence rate would 
be after listening to each of the three statements.17 The 
aim of the study was to determine how much information 
doctors should give patients about statins and their effects 
on cardiovascular outcomes. Each statement gave more 
detailed and complex information on the beneficial effects 
of statins with regard to cardiovascular outcomes. 
The three statements were:
1. Your cardiologist recommends this medication as it 
reduces your risk of myocardial infarction.
2. Within a period of five years, this medication will reduce 
the risk of death caused by heart disease by 42%, and 
the risk of myocardial infarction by 34%. 
3. Without this medication, 88% of patients will still be 
alive after five years. Of those using the medication, 
91% will survive. The risk of myocardial infarction is 
20% if one uses the medication, but 29% for those not 
using the medication. 
Statement 3 describes the benefits of statins most accurately 
as it presents the absolute risk reductions within a given time 
frame, yet most patients thought that they would be most 
likely to take the statin following a simple recommendation 
from their cardiologist (Statement 1). In an earlier part of 
the questionnaire, most patients indicated that they wanted 
detailed information about their treatment and the expected 
benefits. Therefore, patients’ reactions to being given the 
detailed information that they requested is not always easy 
to predict. Some may have struggled to understand the 
detailed information, resulting in most of them indicating 
that they thought a clear, simple recommendation from their 
cardiologist (Statement 1) would “work best” for them. This 
study should not be taken to support a paternalistic “doctor 
knows best” attitude, but it serves as a worthwhile reminder 
that the information supplied should be tailored for each 
patient individually, with the patient indicating what level of 
detail he or she desires. 
Improving statin adherence and 
persistence
Patients currently taking statins are more likely to persist 
with their medication than those who initiated statin 
therapy a decade ago, but statin persistence remains far 
from satisfactory.18,19 Improving adherence and persistence 
remains a major clinical challenge. Interventions to improve 
lipid-lowering medication adherence were examined in a 
recent Cochrane review.20 
Possible interventions aimed at improving adherence 
could include a simplified drug regimen, increased patient 
education and information, intensified patient care, with 
more frequent follow-up and medication reminders, complex 
behavioural interventions such as group sessions, decision 
support systems for doctors, and improved administrative 
efficiency. The first four interventions have been studied 
either alone, or in combination, in a total of 11 randomised 
controlled trials. 
Patient reminders and treatment re-enforcement was 
studied in six studies, and found to be effective in most. The 
studied interventions included regular telephone calls by a 
practice nurse, regular review by a community pharmacist, 
and providing a medication calendar when patients filled 
their first prescription. The absolute increase in adherence 
was mostly modest, but large enough to reach statistical 
significance. Other potential interventions have not been 
as extensively evaluated, and lack published evidence of 
benefit.20,21
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The Adherence Estimator is a brief questionnaire that can 
be applied in everyday clinical practice to assess the risk of 
nonadherence in a given patient.22 
The questionnaire assesses the patient’s perception of 
treatment in three critical areas: the need for medication, 
concern about medication, and affordability of medication.
These areas can also be covered informally when discussing 
treatment with the patient. If the patient perceives any one 
of these treatment aspects negatively, then the risk of 
nonadherence is high, and additional information and an 
explanation should be offered. Patients should be offered 
follow-up appointments, and receive treatment reminders 
where feasible. However, in clinical practice there is not a 
single solution that works for all patients, and judging which 
information and support each patient needs to ensure that 
he or she continues to take his or her medication, falls more 
within the “art of medicine” than the “science of medicine”. 
Adverse effects of statins
Searching Google for “statin side-effects” returns more than 
half a million hits. Separating fact, fiction and speculation 
is almost impossible for the lay reader. Take, for example, 
the often-claimed link between statins and motor neuron 
disease.23,24 Motor neuron disease is a rare disorder, 
but statins are prescribed to millions of patients, so it is 
expected that some patients on statins will develop motor 
neuron disease. The critical questions are whether the rate 
in patients taking statins is higher, and whether this is due 
to the statin itself, or whether statin users are affected by 
other characteristics that increase the likelihood that they 
will develop motor neuron disease. Proving or refuting the 
association beyond doubt, using the limited data available, 
is almost impossible. From the available data, one can only 
conclude that if statins have an effect on increasing the risk 
of motor neuron disease, it is very small.24 This article will 
not review all the potential adverse effects of statins, but will 
focus on myopathy and hepatotoxicity. For a comprehensive 
review of all adverse effects attributed (with varying degrees 
of plausibility) to statins, see the article by Golomb and 
Evans. This article has 892 references.25
Muscle-related problems
Statin-related muscle problems are the most common 
adverse effect of statin therapy. Although there is no 
universally accepted definition of statin myopathy, generally, 
the following categorisation is used clinically.26 Myopathy is 
an overarching term that describes all statin-related muscle 
disorders. While myalgia is muscle pain without elevation 
of the creatine kinase (CK), myositis is muscle pain with 
enzyme elevation, and rhabdomyolysis is characterised 
by extreme CK elevation [usually more than ten times the 
upper limit of normal (ULN)], with a rise in creatinine and 
positive urine myoglobin. 
The reported incidence of myopathy in clinical studies 
is often no different between patients allocated statins 
and those on placebo.27 However, some epidemiological 
studies report myopathy rates to be as high as 5-10%.28,29 
Many trials exclude patients at high risk of myopathy, 
especially those with previous myopathy, and with a statin 
run-in period. Statin-intolerant patients are excluded from 
randomisation. Furthermore, many trials only report myositis 
with CK elevation, rather than myalgia, which is much more 
common. Therefore, statin myopathy is more common in 
clinical practice than suggested by trial data, but the rates 
of rhabdomyolysis are very low (about 0.1-0.2 cases per 1 
000 person years) in all types of studies.30
Patients with statin myopathy commonly complain of muscle 
pain that is most prominent around the hips and shoulders, 
but may involve any muscles. The pain is often described 
as aching, heaviness, tiredness or cramping, often in 
association with stiffness. The intensity of the pain can be 
quite variable, ranging from a mild ache to incapacitating 
pain that confines patients to bed. Myopathy often occurs 
soon after treatment initiation, but may occasionally occur 
after a long lag period. Symptoms usually improve rapidly, 
within days, when statins are stopped (dechallenge). 
Patients with persistent symptoms, elevated CK, and 
especially weakness after statin withdrawal, should be 
evaluated further, as many of them have undiagnosed 
neuromuscular disorders.30,31 See Table I for risk factors for 
statin myopathy
Table I: Risk factors for statin myopathy30
Patient-related Treatment-related
Advanced age Statin dose
Female sex
Low body mass aConcomitant medications
Frail with multi-system disorders Fibrates
Hypothyroid Cyclosporin
Alcohol abuse Antifungals
Very active physically Macrolide antibiotics
bHigh intake of pure grapefruit juice HIV protease inhibitors
Previous statin myopathy Nefazodone




a = Interactions vary according to the statin prescribed. Not all statins interact with all 
medications in the list. Lovastatin, simvastatin, and to a lesser extent, atorvastatin, are highly 
reliant on CYP3A4 hepatic isoenzyme metabolism. Most enzyme inhibitors inhibit the CYP3A4 
isoenzyme, and the abovementioned statins are frequently involved in drug interactions
b = Most grapefruit juice sold in South Africa is not pure, but manufactured using deflavoured 
apple or grape juice as a base
c = Polymorphism in SLCO1B1 (an organic anion-transporting polypeptide) has been associated 
with simvastatin-related myopathy.32
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The management of statin-related myopathy can be 
difficult and frustrating at times. There are guidelines on 
the management of statin-associated myopathy, but these 
guidelines differ in many respects.33,34 This is perhaps not 
surprising, considering that many of the recommendations 
are based on expert opinion, rather than on clinical trial data. 
The approach suggested in this article is based on review 
of the available guidelines, together with local experience at 
the Groote Schuur Hospital Lipid Clinic. 
Measuring a baseline CK before the patient starts statins 
is useful as it alerts one to possible undiagnosed muscle 
disease, and provides a reference point against which 
further measurements can be compared. It is not necessary 
to routinely measure CK on follow-up in patients who 
tolerate statins well. In patients with muscle symptoms, the 
first, and often neglected, step is to confirm that the patient 
has a valid indication for statin therapy. Statin therapy may 
have been started without proper risk assessment, and the 
myopathy may be resolved simply by discontinuing the 
statin permanently. 
Patients with a valid statin indication and muscle symptoms 
should have their CK measured. The location and severity 
of the muscle pain should be assessed. Other causes 
of musculoskeletal pain should be considered and 
appropriately evaluated. Table II lists selected causes of 
non-statin muscle pain. 
It is important to specifically ask patients whether they have 
discontinued the statin themselves at any stage. Rapid 
symptomatic improvement on dechallenge, and recurrent 
symptoms with rechallenge, strongly support the diagnosis 
of statin myopathy. Patients with persistent symptoms 
several weeks after statin discontinuation are less likely to 
have statin myopathy, especially if there were pre-existent 
symptoms before statin initiation. Our experience is that the 
two most common, identifiable alternative diagnoses are 
hypothyroidism and fibromyalgia. If the thyroid-stimulating 
hormone has not been measured recently, then testing 
should be strongly considered as hypothyroidism is easy to 
miss. Patients with definite muscle weakness (not due to the 
patient withholding making a full effort due to pain) should 
proceed rapidly to a complete neuromuscular evaluation, 
as statin myopathy seldom causes definite weakness, 
and such patients often have undiagnosed neuromuscular 
disorders.35
If no alternative causes for the symptoms are identified, 
further management depends on the severity of symptoms 
and the CK. Patients with mild and tolerable symptoms, and 
a CK < 5 x ULN, can continue with the statin, but caution 
should be exercised when increasing the statin dose further. 
If the symptoms are severe, then statin discontinuation 
should be considered irrespective of the CK. The CK 
correlates poorly with symptoms, and patients may have 
disabling symptoms despite a normal CK. Statins are 
generally withheld until muscle symptoms have resolved. 
Once patients have recovered, alternative strategies can be 
considered (see below). 
If CK elevation is found in asymptomatic patients, alternative 
explanations should be sought (see Table I). Unaccustomed 
or excessive exercise, e.g. weightlifting and horse riding, 
can elevate the CK markedly. The statin does not need to 
be discontinued if the elevated CK is readily explicable. 
Anecdotally, some patients who engage in very vigorous 
exercise report better performance and faster recovery if 
they discontinue the statin for a few days before and after 
a major sporting event, such as a marathon or triathlon. If 
the CK < 5 x ULN, the statin can be continued, but ongoing 
CK monitoring should be considered, especially if the 
statin dose is increased. Asymptomatic patients with an 
unexplained CK > 10 x ULN should temporarily discontinue 
the statin. Asymptomatic patients with a CK 5-10 x ULN 
should be monitored closely for a low threshold for dose 
reduction, or temporary discontinuation. 
Alternative management strategies
Statins are the most effective low-density lipoprotein (LDL) 
cholesterol-lowering agents available, and their outcome 
benefit is well documented.36,37 Therefore, this drug class 
should not be abandoned before alternative statin strategies 
have been tried. Patients need to understand that finding 
a suitable statin at a tolerable dose is often a process of 
trial and error. It is important to proceed systematically, with 
good documentation of symptoms and lipid responses. 






Cortisol excess or deficiency
Vitamin D deficiency




Autoimmune disorders, e.g. systemic lupus erythematosus 
Musculoskeletal disorders, e.g. bursitis and tendonitis
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There are three main alternative statin strategies that can 
be tried, either alone or in combination. The original statin 
can be prescribed at a reduced dose, an alternative statin 
can be prescribed (usually started at a lower effective 
dose than the previous statin), or non-daily dosing can be 
tried. If myopathy occurred when the dose of a previously 
well-tolerated statin was increased, down titration is often 
effective. 
Statin-switching strategies have been tested in a limited 
number of studies, but trials with fluvastatin and rosuvastatin 
show that switching the statin can be successful in some 
patients with myopathy.38,39 The new statin is generally 
started at a lower effective dose (a dose that will reduce 
the LDL cholesterol less). It can be difficult to determine 
whether it was the change in statin, or the dose reduction, 
that resulted in resolution of myopathy. Some medications 
(see Table I) interfere with statin metabolism, and a statin 
that does not interact with the patient’s other medication, 
should be chosen. 
Patients who cannot tolerate daily statin dosing may be 
prescribed statins on alternate days, or even as infrequently 
as once weekly. Non-daily dosing has been tried, mainly with 
atorvastatin and rosuvastatin due to their long half-lives.40-43 
Modest, but clinically useful LDL cholesterol reductions are 
achievable with non-daily dosing. 
Using the strategies described above, it is usually possible 
to determine the maximum tolerable statin dose. If the LDL 
cholesterol remains unacceptably high, ezetimibe may be 
added to the statin.44,45 Ezetimibe reduces cholesterol by 
inhibiting intestinal cholesterol absorption. Its mechanism 
of action is different from that of statins, and its use is 
infrequently associated with myopathy. Ezetimibe is only 
available as a fixed 10 mg daily dose, and adverse effects 
are uncommon.46 Because ezetimibe is a relatively new 
drug, it still lacks cardiovascular outcome evidence. 
Ezetimibe monotherapy is an option in patients who do 
not tolerate statins at all. Ezetimibe monotherapy reduces 
LDL cholesterol by about 18%, and it is often impossible 
to achieve complete LDL cholesterol control in patients 
who are completely intolerant to statins.47 Bile acid 
sequestrants also lower LDL cholesterol. The only bile acid 
sequestrant available in South Africa is cholestyramine. Its 
utility is limited, as bloating and constipation are frequent 
adverse effects. Cholestyramine may also interfere with the 
absorption of other drugs. 
Coenzyme Q10
Coenzyme Q10, or ubiquinone, is an end-product of 
mevalonate synthesis. Coenzyme Q10 is a component of 
the mitochondrial electron transport system, and therefore 
important for mitochondrial functioning. Statins inhibit 
mevalonate synthesis, and can potentially reduce coenzyme 
Q10 levels.48,49 About 50% of coenzyme Q10 is thought to 
be endogenously synthesised, with the other 50% obtained 
from dietary uptake.50
Statins lower the serum levels of coenzyme Q10. This 
is mainly accounted for by the reduced LDL cholesterol 
associated with statin therapy, as LDL cholesterol is 
the major plasma carrier of coenzyme Q10. Whether 
statins reduce the intramuscular or mitochondrial levels 
of coenzyme Q10 is debatable. The majority of studies 
have found no association. Whether patients with statin 
myopathy have lower intramuscular coenzyme Q10 levels 
is also a matter of debate, as both positive and negative 
studies have been published. (Marcoff and Thompson48 and 
Schaars and Stalenhoef49 have reviewed the Q10 literature, 
if further reading is required). 
The clinically more relevant question, namely whether 
supplementation with coenzyme Q10 will prevent statin 
myopathy or improve symptoms in those with myopathy, 
has unfortunately also not been definitively answered. 
Several small trials have been conducted. One trial 
compared coenzyme Q10 with vitamin E in 32 patients with 
statin myopathy. Pain scores decreased from baseline in 
the coenzyme Q10 arm, but remained unchanged in the 
vitamin E group.51 Another study compared coenzyme Q10 
to placebo in 44 patients with statin myopathy treated with 
simvastatin. There were no outcome differences (pain score 
or number of patients adhering to their statin treatments) 
between placebo and coenzyme Q10.52 In yet another study, 
coenzyme Q10 was compared to placebo in patients on 
atorvastatin. In this study, muscle and liver enzyme values 
were the major end-points, and once again, no difference 
could be found between placebo and coenzyme Q10.53 
Several further studies of coenzyme Q10 are ongoing, 
and their results are awaited. Currently, the evidence 
that coenzyme Q10 is beneficial is inconclusive at best, 
and routine supplementation cannot be recommended. 
Coenzyme Q10 has no known adverse effects, except for 
the significant financial outlay required, and some patients 
report a symptomatic benefit. This is probably due to the 
placebo effect in many cases. 
Red yeast rice
Red yeast rice is a popular, lipid-lowering dietary 
supplement that is freely available at most health stores. It 
is made by fermenting the yeast, Monascus purpureus, over 
rice, and has been used as a dietary supplement in China 
for centuries. This yeast secretes a family of substances 
called monacolins. One of the monacolins (monacolin K) is 
identical to lovastatin. Lovastatin production varies between 
different strains of the yeast, and the amount of lovastatin 
found in commercially available red yeast rice capsules is 
also highly variable. 
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Red yeast rice lowers LDL cholesterol,54,55 and a partially 
purified red yeast rice extract (Xuezhikang) has been shown 
to reduce cardiovascular end-points in a Chinese post-
infarction population.56 Several small trials have investigated 
the use of red yeast rice in patients with statin myopathy.57-59 
Becker et al randomised 62 statin-intolerant patients to 
red yeast rice or placebo. LDL cholesterol was lowered by 
0.90 mmol/l in the red yeast rice group, and by 0.39 mmol/l 
in the placebo group at week 24. Pain scores and CK did 
not differ between the groups.57 In another study, red yeast 
rice was compared with pravastatin 20 mg, twice daily, in 43 
statin-intolerant patients. LDL cholesterol reductions, pain 
scores and CK measurements did not differ between the 
two groups.58
However, red yeast rice should be regarded as a 
medication, and not a dietary supplement. It is neither free 
of adverse effects, nor perfectly safe. Myopathy, including 
rhabdomyolysis, can occur in red yeast rice users,60,61 
and hepatitis has also been described.62 As red yeast 
rice production is largely unregulated, concentrations of 
the active ingredients can vary markedly among different 
commercial preparations. Some preparations also contain 
citrinin, which is a nephrotoxin.63 Ideally, red yeast rice 
production needs to be standardised and regulated, 
followed by adequately powered safety and efficacy trials. 
Patients who want to take red yeast rice preparations should 
be informed that currently, red yeast rice is not adequately 
regulated or standardised. Although red yeast rice can be 
obtained without a prescription, it may still cause adverse 
effects. 
Hepatotoxicity
Statins are regarded as “hepatotoxic” by many doctors and 
patients. Such concerns are often unfounded and excessive, 
and may at times even cause doctors to withhold statins 
when they are indicated, and their use would be entirely 
safe.64,65 Statins may cause mild elevations in alanine 
aminotransferase (ALT) in up to 10% of recipients, and in 
1-3% of patients, the ALT may be more than 3 x ULN.66 
This transaminitis is often seen in the first three months 
of therapy. However, such ALT elevations do not translate 
into clinical liver disease or liver failure.67 The rate of acute 
liver failure in statin users is not higher than the background 
population rate.68 This does not mean that statins never 
cause liver injury. There are definitely cases in which liver 
injury was most probably due to statin therapy.69 However, 
these cases are extremely rare, and statins should not be 
regarded as more hepatotoxic than most other commonly 
used drugs. 
Abnormal liver function tests in patients taking statins 
are often ascribed to the statin. This approach may do 
more harm than the statin itself, as it may lead to a failure 
to investigate and identify potentially treatable causes. 
Persistent liver function abnormalities in patients on statins 
should be investigated in the same way as in patients on 
no medication. If the ALT > 3 x ULN, the statin should be 
temporarily discontinued, and investigations into other 
causes of transaminitis requested. The patient can then be 
rechallenged with statins once the ALT has normalised. Liver 
function tests should be monitored following rechallenge to 
ensure continued normalisation. 
Patients with elevated transaminases measured at baseline 
often pose a management dilemma, with physicians 
concerned about the risk of exacerbating the liver disease. 
Elevated baseline liver function tests are not uncommon in 
clinical practice, as many patients at high cardiovascular 
risk have other disorders such as non-alcoholic fatty liver 
disease, chronic viral hepatitis and iron overload. These 
patients are often denied statins for fear of worsening 
their hepatic disease. Patients with persistently elevated 
liver function tests should be investigated to identify the 
underlying cause of liver disease, and its severity. If the liver 
disease is stable and compensated carefully, supervised 
statin therapy can be initiated. This recommendation is 
discordant with the approved label (package insert) of most 
statins, which contraindicates their use in chronic liver 
disease. However, an expert panel of hepatologists recently 
reviewed all available statin safety data, and concluded that 
stable chronic liver disease and compensated cirrhosis are 
not contraindications to statin therapy.70 Subsequently, this 
approach has been supported by many other authors.64,69,71-74
Whether, when and how often liver function tests should 
be monitored in patients on statins is controversial. 
The National Cholesterol Education Panel guidelines 
recommend baseline testing, a test at 12 weeks, and then 
annual monitoring.75 However, the clinical value of such 
an approach is questionable, as there is no evidence that 
routine monitoring identifies patients at risk of serious 
toxicity. Statins have an excellent hepatic safety record, and 
in many studies, persistently elevated liver enzymes have 
turned out to be false positives.76 Baseline testing makes 
sense as it provides a reference for future comparison, and 
may lead to the identification of undiagnosed liver disease. 
Further monitoring should be individualised.33
Conclusion
Statins have an excellent and well-established safety record. 
In clinical practice, myopathy is the most bothersome side-
effect, but this problem can be resolved or ameliorated in 
many patients. However, there is a small group of patients 
who remain completely intolerant to statins. These patients 
have limited treatment options, including ezetimibe and 
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cholestyramine, and their LDL cholesterol often cannot 
be well controlled. Statins are not particularly hepatotoxic 
drugs, and hepatic adverse events that preclude statin 
prescription are very rare. Statins may occasionally 
cause other adverse effects, e.g. simvastatin may cause 
headaches in some patients, which has not been discussed 
in this article. These other adverse effects are not likely to 
be class-related, and a statin switch will often solve the 
problem. 
When dealing with patients on statins, clinicians often 
tends to focus on those who report adverse effects. Just 
as important, if not more important, are those patients who 
have quietly stopped taking their statins. Patients will often 
not inform their doctor that they have stopped the statin, 
and may even continue coming in for prescriptions that they 
never fill. Lipid management does not end when the first 
prescription has been written, but requires regular follow-up 
with monitoring of lipids (adequacy of treatment, adherence 
and persistence) and direct questions about adherence and 
persistence. Ensuring adherence and persistence is often 
a greater clinical challenge than dealing with the adverse 
effects. 
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